Bioactive Compounds and Nanodelivery Perspectives for Treatment of Cardiovascular Diseases

Sindhu R. K., Goyal A., Algin Yapar E., Cavalu S.

APPLIED SCIENCES-BASEL, cilt.11, sa.22, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 11 Sayı: 22
  • Basım Tarihi: 2021
  • Doi Numarası: 10.3390/app112211031
  • Dergi Adı: APPLIED SCIENCES-BASEL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Aerospace Database, Agricultural & Environmental Science Database, Applied Science & Technology Source, Communication Abstracts, INSPEC, Metadex, Directory of Open Access Journals, Civil Engineering Abstracts
  • Anahtar Kelimeler: bioactive compounds, cardiovascular, nanodelivery, bioavailability, SOLID LIPID NANOPARTICLES, CORONARY HEART-DISEASE, BETA-CAROTENE, DELIVERY-SYSTEMS, RISK-FACTORS, OXIDATIVE MODIFICATION, ANTIOXIDANT ACTIVITY, DIETARY FLAVONOIDS, VASCULAR FUNCTION, WINE POLYPHENOLS
  • Sivas Cumhuriyet Üniversitesi Adresli: Hayır

Özet

Bioactive compounds are comprised of small quantities of extra nutritional constituents providing both health benefits and enhanced nutritional value, based on their ability to modulate one or more metabolic processes. Plant-based diets are being thoroughly researched for their cardiovascular properties and effectiveness against cancer. Flavonoids, phytoestrogens, phenolic compounds, and carotenoids are some of the bioactive compounds that aim to work in prevention and treating the cardiovascular disease in a systemic manner, including hypertension, atherosclerosis, and heart failure. Their antioxidant and anti-inflammatory properties are the most important characteristics that make them favorable candidates for CVDs treatment. However, their low water solubility and stability results in low bioavailability, limited accessibility, and poor absorption. The oral delivery of bioactive compounds is constrained due to physiological barriers such as the pH, mucus layer, gastrointestinal enzymes, epithelium, etc. The present review aims to revise the main bioactive compounds with a significant role in CVDs in terms of preventive, diagnostic, and treatment measures. The advantages of nanoformulations and novel multifunctional nanomaterials development are described in order to overcome multiple obstacles, including the physiological ones, by summarizing the most recent preclinical data and clinical trials reported in the literature. Nanotechnologies will open a new window in the area of CVDs with the opportunity to achieve effective treatment, better prognosis, and less adverse effects on non-target tissues.